At Lucky Core Industries, I coordinated the acquisition of Pfizer’s manufacturing facility and product portfolio, supporting integration planning, stakeholder alignment, and execution tracking. I also coordinated the transfer of products and machinery from three manufacturing plants into the acquired facility.
I designed and led the Gross Margin Improvement initiative, bringing senior leadership and department heads together to develop financial savings and strategic improvement ideas. The initiative pipeline targeted more than PKR 300 million in value realization by July 2026.
Before Lucky Core Industries, I managed trade finance transactions exceeding $500 million at Scotiabank and streamlined processes to reduce processing time. At Home Trust Canada, I processed investment services transactions and conducted reviews to meet Anti-Money Laundering requirements.

